^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | Fotivda (tivozanib) (VEGFR-2 inhibitor, VEGFR-1 inhibitor, VEGFR-3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
06/17/2022
Excerpt:
Principles of systemic therapy for relapse or stage IV disease...Subsequent therapy for clear cell histology...Other recommended regimes: Tivozanib (category 1)
Source:
Published date:
09/28/2021
Excerpt:
First-line treatment for advanced ccRCC...Sunitinib [I, A], pazopanib [I, A] and tivozanib [II, B; ESMO-MCBS v1.1 score: 1] are alternatives to PD-1 inhibitor-based first-line combinations when immune therapy is contraindicated or not available.
